News for Gilead Sciences, Inc. - Google Finance

GILEAD SCIENCES, INC. : European Medicines Agency Validates Gilead's ...

Tue, 21 May 2013 22:02:23 GMT

GILEAD SCIENCES, INC. : European Medicines Agency Validates Gilead's ...
4-traders (press release) - 5 hours ago

21, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Marketing Authorisation Application (MAA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus (HCV) infection ...

Gilead Hepatitis C Drug Gets Accelerated Review - Fox Business
EMA Validates Gilead's Marketing Application For Sofosbuvir - RTTNews - RTT News

Gilead Sciences, Inc. (NASDAQ:GILD) Investor Alert: Investigation over ...

Tue, 21 May 2013 12:13:26 GMT

Gilead Sciences, Inc. (NASDAQ:GILD) Investor Alert: Investigation over ...
SBWire (press release) - 15 hours ago

An investigation for investors in Gilead Sciences, Inc. (NASDAQ:GILD) shares over potential securities laws violations by Gilead Sciences, Inc. was announced and NASDAQ:GILD stockholders should contact the Shareholders Foundation at ...

News Behind Insider Trading: American International Group, First Solar, Gilead ... - Wall Street Journal (press release)
Gilead Sciences Stock Rating Reaffirmed by JPMorgan Chase (GILD) - Mideast Time

GILEAD SCIENCES, INC. : Gilead Sciences to Present at the 2013 UBS Global ...

Fri, 17 May 2013 20:11:35 GMT

GILEAD SCIENCES, INC. : Gilead Sciences to Present at the 2013 UBS Global ...
4-traders (press release) - May 17, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 2013 UBS Global Healthcare Conference in New York.

GILEAD SCIENCES, INC. : Gilead Announces Response Data from Phase 2 ...

Wed, 15 May 2013 22:36:38 GMT

GILEAD SCIENCES, INC. : Gilead Announces Response Data from Phase 2 ...
4-traders (press release) - May 15, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with ...

Gilead Sciences To Present At UBS Global Conference; Webcast At 9:30 AM ET

Mon, 20 May 2013 11:33:54 GMT

Gilead Sciences To Present At UBS Global Conference; Webcast At 9:30 AM ET
NASDAQ - May 20, 2013

loading. (RTTNews.com) - Gilead Sciences Inc. ( GILD ) will present at the 2013 UBS Global Healthcare Conference in ,New York City .

Gilead Sciences, Inc. (GILD) Call Traders Target New Highs

Tue, 14 May 2013 13:20:34 GMT

Gilead Sciences, Inc. (GILD) Call Traders Target New Highs
Schaeffers Research - May 14, 2013

Calls were the options of choice on Gilead Sciences, Inc. (NASDAQ:GILD) yesterday, with roughly 27,000 contracts crossing the tape during the course of the session.

Reveal Insider Trading in JC Penney, Gilead Sciences, Chesapeake Energy ...

Tue, 14 May 2013 12:55:57 GMT

Reveal Insider Trading in JC Penney, Gilead Sciences, Chesapeake Energy ...
MarketWatch (press release) - May 14, 2013

Gilead Sciences, Inc. (NASDAQ:GILD) : By the end of last trading session, Gilead Sciences (NASDAQ:GILD) shares earned US$1.59 (or 3.01%) to US$54.47 with about 14.49 million shares exchanged hands for the session, compared to its average volume of ...

Theravance Inc. (NASDAQ:THRX), Gilead Sciences Inc. (NASDAQ:GILD), and ...

Mon, 13 May 2013 18:57:47 GMT

Theravance Inc. (NASDAQ:THRX), Gilead Sciences Inc. (NASDAQ:GILD), and ...
SBWire (press release) - May 13, 2013

Gilead Sciences Inc. (NASDAQ:GILD) a biopharmaceutical company that discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia is currently up (+2.94%) on 10,887,989 ...

Gilead Sciences Inc. (GILD) Has Climbed To A New High On Q1 Results

Fri, 03 May 2013 14:18:52 GMT

Gilead Sciences Inc. (GILD) Has Climbed To A New High On Q1 Results
RTT News - May 3, 2013

Gilead Sciences Inc. (GILD: Quote) reported first quarter adjusted EPS of $0.48 after the close Thursday, compared to $0.45 in the prior year period.

Gilead Sciences climbs to all-time highs - Businessweek
Gilead combo hepatitis C pill effective in small trial - Reuters

Gilead Sciences To Present At Bank Of America Conference;Webcast At 12:20 ...

Wed, 15 May 2013 15:27:26 GMT

Gilead Sciences To Present At Bank Of America Conference;Webcast At 12:20 ...
NASDAQ - May 15, 2013

(RTTNews.com) - Gilead Sciences Inc. ( GILD ) will present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.